SBIR Phase I: Bioluminescence Resonance Energy Transfer Assays for Clinical Chemistry

Award Information
Agency:
National Science Foundation
Branch
n/a
Amount:
$99,993.00
Award Year:
2007
Program:
SBIR
Phase:
Phase I
Contract:
0711621
Agency Tracking Number:
0711621
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Zymera Corporation
25 Bear Paw, UAMS/BioVentures, san jose, CA, 95138
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
171080885
Principal Investigator:
Daniel Sobek
DPhil
(650) 515-7897
daniel_sobek@zymera.com
Business Contact:
Daniel Sobek
DPhil
(650) 515-7897
daniel_sobek@zymera.com
Research Institution:
n/a
Abstract
This Small Business Innovation Research (SBIR) Phase I research project aims to develop a point-of-care assay for creatine kinase, an important toxicity biomarker, to screen for adverse drug reactions (ADRs) using whole blood. The assay will utilize bioluminescent resonance energy transfer (BRET) probes incorporating quantum dots. The proposed technology is likely to impact toxicity testing, allowing physicians to test for potential ADR at an early stage and take corrective measures. With over 50% of Medicare patients taking multiple medications, the probability of ADRs is high and any inexpensive and reliable test for toxicity would be of benefit to these individuals and society as a whole.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government